ATNM
Actinium Pharmaceuticals, IncstockNYSEAMERICAN
actinium pharmaceuticals, inc. (www.actiniumpharma.com) (nyse mkt: atnm) is a new york-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. the company's lead radiopharmaceutical iomab™-b will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. the company is preparing a single, pivotal, multicenter phase 3 clinical study of iomab™-b in refractory and relapsed acute myeloid leukemia (aml) patients over the age of 55 with a primary endpoint of durable complete remission. the company's second program, actimab-a, is continuing its clinical development in a phase 1/2 trial for newly diagnosed aml patients o
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 1.57 | 2026-11-10 | -15.29% | 3.155 |
| 1M | 1.13 | 2026-10-16 | +17.70% | 1.694 |
| 3M | 1.05 | 2026-08-17 | +26.67% | 1.146 |
| 6M | 1.17 | 2026-05-18 | +13.68% | 0.645 |
| 1Y | 1.45 | 2025-11-17 | -8.28% | 0.738 |
| 2Y | 1.42 | 2024-11-18 | -6.34% | — |
| 5Y | 7.78 | 2021-11-17 | -82.91% | 1.171 |
Actinium Pharmaceuticals, Inc (NYSEAMERICAN:ATNM) stock price today is $1.33, and today's volume is 552,412. ATNM is down 10.738% today. The 30 day average volume is 242,052. ATNM market cap is $41.82M with 31.44M shares outstanding.
